GB9723780D0 - Regulation of ocular angiogenesis - Google Patents

Regulation of ocular angiogenesis

Info

Publication number
GB9723780D0
GB9723780D0 GB9723780A GB9723780A GB9723780D0 GB 9723780 D0 GB9723780 D0 GB 9723780D0 GB 9723780 A GB9723780 A GB 9723780A GB 9723780 A GB9723780 A GB 9723780A GB 9723780 D0 GB9723780 D0 GB 9723780D0
Authority
GB
United Kingdom
Prior art keywords
neovascularisation
ocular angiogenesis
regulation
compounds
retinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB9723780A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Priority to GB9723780A priority Critical patent/GB9723780D0/en
Publication of GB9723780D0 publication Critical patent/GB9723780D0/en
Priority to AU10436/99A priority patent/AU1043699A/en
Priority to PCT/GB1998/003354 priority patent/WO1999024056A1/en
Ceased legal-status Critical Current

Links

Abstract

The invention concerns compounds that modulate Placenta Growth Factor activity and the use of such compounds for the manufacture of a medicament for treating conditions at least partially characterised by abnormal ocular angiogenesis such as retinal neovascularisation, subretinal neovascularisation, glaucomatous neovascularisation, rubeosis or corneal neovascularisation. These conditions include Vasoproliferative Retinopathy, especially Proliferative Diabetic Retinopathy.
GB9723780A 1997-11-12 1997-11-12 Regulation of ocular angiogenesis Ceased GB9723780D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9723780A GB9723780D0 (en) 1997-11-12 1997-11-12 Regulation of ocular angiogenesis
AU10436/99A AU1043699A (en) 1997-11-12 1998-11-12 Regulation of ocular angiogenesis
PCT/GB1998/003354 WO1999024056A1 (en) 1997-11-12 1998-11-12 Regulation of ocular angiogenesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9723780A GB9723780D0 (en) 1997-11-12 1997-11-12 Regulation of ocular angiogenesis

Publications (1)

Publication Number Publication Date
GB9723780D0 true GB9723780D0 (en) 1998-01-07

Family

ID=10821888

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9723780A Ceased GB9723780D0 (en) 1997-11-12 1997-11-12 Regulation of ocular angiogenesis

Country Status (3)

Country Link
AU (1) AU1043699A (en)
GB (1) GB9723780D0 (en)
WO (1) WO1999024056A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407858C (en) * 2000-05-12 2015-10-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
WO2004046722A2 (en) 2002-11-16 2004-06-03 Dade Behring Marburg Gmbh Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
NZ561763A (en) 2005-03-24 2009-02-28 Thrombogenics Nv Novel anti PLGF antibody
DE102005022047A1 (en) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use
WO2007003609A1 (en) 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN101534865A (en) 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
MX2011003428A (en) 2008-10-02 2011-07-29 Vib Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia.
PL2785739T3 (en) 2011-12-01 2017-10-31 Thrombogenics Nv Improving trabeculectomy outcome
CA3013808A1 (en) * 2016-03-10 2017-09-14 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CN1209068A (en) * 1995-10-23 1999-02-24 海欧制药澳大利亚有限公司 Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization
ATE343400T1 (en) * 1996-09-24 2006-11-15 Merck & Co Inc COMPOUNDS FOR INHIBITING ANGIOGENESIS BY GENE THERAPY

Also Published As

Publication number Publication date
AU1043699A (en) 1999-05-31
WO1999024056A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
TWI255714B (en) Method for treating meibomian gland disease
AU3613800A (en) Offset ablation profiles for treatment of irregular astigmatism
AU3990797A (en) Sustained release formulation
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
EP1110554A4 (en) Medicinal compositions for treating eye diseases
EP0895781A3 (en) Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
MY138811A (en) Preventive or therapeutic agent for glaucoma
GB9723780D0 (en) Regulation of ocular angiogenesis
EP0879601A3 (en) Ophthalmic drug delivery system
DE60022683D1 (en) NERVOUS PROTECTION PRODUCTS
MX9802817A (en) Carbostyril derivative for curing ophthalmological diseases.
HK1045645A1 (en) Biochemical methods that eliminate corneal scars, opacification and haze
HK1040182A1 (en) Use of staurosporine derivatives for treating ocular neovascular diseases
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
MXPA04001255A (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma.
AU3581695A (en) Method and means for prevention and treatment of secondary cataract
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
MXPA05009492A (en) Thiolactones.
WO2000010605A3 (en) Preventives or remedies for eye circulatory failure
WO2023107653A3 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
ES2289134T3 (en) USE OF NON-FEMINIZING STROGENS AS PROTECTIVE AGENTS OF RETINA FOR THE TREATMENT OF GLAUCOMA.
WO2003020283A3 (en) Method for treating diabetic retinopathy
TW362097B (en) 3-Phenyl-1, 4-dialkyl-1,2,4-triazolium salts and their use as antidepressants

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)